Conversely, inhibition of PI3K pathway components like AKT without inhibition of RAS signaling is unlikely to be efficacious in triple negative breast cancers or lung adenocarcinomas, regardless of KRAS mutation status. The gene discussed is PIK3CA; the disease is lung adenocarcinoma.